Title:
NUCLEIC ACID MOLECULE FOR HEPATITIS B TREATMENT USE
Document Type and Number:
WIPO Patent Application WO/2021/107097
Kind Code:
A1
Abstract:
The present invention provides a nucleic acid molecule which can suppress the amplification of hepatitis B virus DNA significantly. More specifically, the present invention provides a single-stranded nucleic acid molecule which can suppresses the amplification of hepatitis B gene virus DNA, the nucleic acid molecule being characterized by being composed only of a region (X), a linker region (Lx) and a region (Xc), the linker region (Lx) having a non-nucleotide structure containing at least one of a pyrrolidine base structure and a piperidine base structure, and at least one of the region (X) and the region (Xc) comprising a nucleotide sequence composed of at least 18 contiguous bases contained in any one of sequences capable of suppressing the expression of hepatitis B virus gene represented by SEQ ID NOs:1 and 2, human NCAPH gene represented by SEQ ID NOs:3 to 5, human Sp1 gene represented by SEQ ID NOs:6 and 7 and human SOCS7 gene represented by SEQ ID NOs:8 and 9.
Inventors:
EGUCHI YUTAKA (JP)
YASUOKA JUNICHI (JP)
EMURA CHISATO (JP)
YASUOKA JUNICHI (JP)
EMURA CHISATO (JP)
Application Number:
PCT/JP2020/044231
Publication Date:
June 03, 2021
Filing Date:
November 27, 2020
Export Citation:
Assignee:
BONAC CORP (JP)
International Classes:
C12N15/113; A61K31/7125; A61K31/713; A61K48/00; A61P1/16; A61P31/20; A61P35/00
Domestic Patent References:
| WO2018195165A1 | 2018-10-25 | |||
| WO2013159109A1 | 2013-10-24 | |||
| WO2019128611A1 | 2019-07-04 | |||
| WO2018199338A1 | 2018-11-01 |
Foreign References:
| JP2018520685A | 2018-08-02 | |||
| JP2017534290A | 2017-11-24 | |||
| JP2014513954A | 2014-06-19 | |||
| CN107050469A | 2017-08-18 | |||
| CN110496222A | 2019-11-26 | |||
| US20130267575A1 | 2013-10-10 | |||
| US6039955A | 2000-03-21 | |||
| JP2008522951A | 2008-07-03 |
Other References:
GE, DONGXIA ET AL.: "LNCaP prostate cancer cells with autocrine interleukin-6 expression are resistant to IL -6-induced neuroendocrine differentiation due to increased expression of suppressors of cytokine signaling", THE PROSTATE, vol. 72, 2012, pages 1306 - 1316, XP055391181, DOI: 10.1002/pros.22479
VERRIER, ELOI R. ET AL.: "A dual screening approach identifies estrogen receptor 1 as a host factor for hepatitis delta virus infection and a target for antiviral therapy", HEPATOLOGY, vol. 64, no. 1, 2016, pages 302A - 303A
VERRIER, ELOI R. ET AL.: "A dual screening approach identifies estrogen receptor 1 as a host factor for hepatitis delta virus infection and a target for antiviral therapy", HEPATOLOGY, vol. 64, no. 1, 2016, pages 302A - 303A
Attorney, Agent or Firm:
TAKASHIMA, Hajime (JP)
Download PDF: